Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study.

Arintaya PhrommintikulWanwarang WongcharoenSirinart KumfuThidarat JaiwongkamSiriluck GunaparnSiripron C ChattipakornNipon Chattipakorn

Published in: British journal of clinical pharmacology (2019)

The extraglycaemic effects of dapagliflozin and vildagliptin on cardiometabolic parameters in T2D with CAD were different. The more favourable effects of dapagliflozin compared to vildagliptin may have explained the cardiovascular benefits observed only in sodium glucose co-transporter-2 inhibitors.

Keyphrases

clinical trial
coronary artery disease
open label
study protocol
randomized controlled trial